Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
August 27, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregiversApproval...
Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
August 20, 2024 08:30 ET
|
F. Hoffmann-La Roche Ltd
Roche is committed to supporting all those working to overcome the mpox outbreak by providing access to high-quality Polymerase Chain Reaction (PCR) testingRoche confirms that its cobas MPXV test, as...
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
July 30, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept, and robust retinal...
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
July 29, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances.LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics...
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Halbjahr 2024 um 5% (CER); starkes Wachstum im zweiten Quartal – Gewinnprognose für das Gesamtjahr erhöht
July 25, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Konzernverkäufe stiegen im ersten Halbjahr um 5%1 zu konstanten Wechselkursen (CER; stabil in CHF) dank starker Nachfrage sowohl nach Medikamenten als auch nach Diagnostika; ohne COVID-19-Produkte...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
July 25, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products,...
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
July 18, 2024 07:20 ET
|
F. Hoffmann-La Roche Ltd
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR)Safety data were...
Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
July 17, 2024 11:45 ET
|
F. Hoffmann-La Roche Ltd
More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpointPeople treated with Vabysmo sustained vision gains and anatomical improvements, with almost 80%...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
July 17, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001)1 Pharmacokinetic data supports a once-daily oral dosing...
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
July 09, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy.The built-in AI-trained...